Outlook Therapeutics (OTLK) Stock Price, News & Analysis

Company Overview

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Key Stats

• Today's Range: $1.24 to $1.55
• 50-Day Range: $1.38 to $2.30
• 52-Week Range: $0.87 to $12.85
• Volume: 1.27 million shs
• Average Volume: 749,332 shs
• Market Capitalization: $47.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.20
• Consensus Rating: Moderate Buy

Outlook Therapeutics Stock Analysis - MarketRank™

Outlook Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 737th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Outlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Outlook Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Outlook Therapeutics are expected to grow in the coming year, from ($2.27) to ($0.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Outlook Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Outlook Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.84% of the float of Outlook Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Outlook Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Outlook Therapeutics has recently decreased by 0.85%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Outlook Therapeutics does not currently pay a dividend.

Dividend Growth

Outlook Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.84% of the float of Outlook Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Outlook Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Outlook Therapeutics has recently decreased by 0.85%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: 0.13

News Sentiment

Outlook Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Outlook Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 13 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Outlook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Outlook Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.80% of the stock of Outlook Therapeutics is held by insiders.

Percentage Held by Institutions

Only 11.20% of the stock of Outlook Therapeutics is held by institutions.

OTLK Stock Analysis - Frequently Asked Questions

How have OTLK shares performed this year?

Outlook Therapeutics' stock was trading at $1.89 on January 1st, 2025. Since then, OTLK shares have decreased by 20.9% and is now trading at $1.4950.
View the best growth stocks for 2025 here.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) posted its earnings results on Friday, February, 14th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.04.

When did Outlook Therapeutics' stock split?

Outlook Therapeutics's stock reverse split on Thursday, March 14th 2024. The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Outlook Therapeutics' major shareholders?

Outlook Therapeutics' top institutional investors include Rhumbline Advisers (0.59%), Tang Capital Management LLC (0.57%), Renaissance Technologies LLC (0.41%) and Northern Trust Corp (0.35%). Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Lawrence A Kenyon, Yezan Munther Haddadin and C Russell Trenary III.
View institutional ownership trends.

How do I buy shares of Outlook Therapeutics?

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Outlook Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 2/14/2025
• Today: 3/24/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OTLK
• CIK: 1649989
• Web: www.outlooktherapeutics.com
• Phone: (609) 619-3990
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.20
• High Stock Price Target: $24.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +618.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($7.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-75,370,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -225.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.32
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.57) per share
• Price / Book: -0.90

Miscellaneous

• Outstanding Shares: 32,017,000
• Free Float: 30,480,000
• Market Cap: $45.46 million
• Optionable: Optionable
• Beta: 0.54